Evidence map›Paper›PMID 40416730›Full record

ArticleInternational journal of nanomedicine2025

Anti-Infection Efficacy, Osteogenesis Potential, and Biocompatibility of 3D Printed PLGA/Nano-Hydroxyapatite Porous Scaffolds Grafted with Vancomycin/DOPA/rhBMP-2 in Infected Rabbit Bone Defects.

A Li Mu Ke Re Mu, Maimaitiaili Abulikemu, Zhilin Liang, Abudurusuli Abulikemu, Aikebaier Tuxun

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Glucose metabolism in osteoporosis: A potential therapeutic target (Review).International journal of molecular medicine · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A Li Mu Ke Re MuDepartment of Orthopedic, First People's Hospital of Kashgar, Kashgar, Xinjiang, 844000, People's Republic of China.
Maimaitiaili AbulikemuDepartment of Trauma Orthopaedics, First People's Hospital of Kashgar, Kashgar, Xinjiang, 844000, People's Republic of China.
Zhilin LiangDepartment of Trauma Orthopaedics, First People's Hospital of Kashgar, Kashgar, Xinjiang, 844000, People's Republic of China.
Abudurusuli AbulikemuDepartment of Trauma Orthopaedics, First People's Hospital of Kashgar, Kashgar, Xinjiang, 844000, People's Republic of China.
Aikebaier TuxunDepartment of Trauma Orthopaedics, First People's Hospital of Kashgar, Kashgar, Xinjiang, 844000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Given the limitations of traditional therapies, the treatment of infected bone defects (IBD) remains a great challenge. It is urgent to find a novel method that can simultaneously eradicate infection and promote new bone formation. With the increasing application of personalized scaffolds in orthopedics, novel biomaterials with both antibacterial and osteoinductive properties have provided a viable option for IBD treatment. Through the three-dimensional (3D) printing technology, we fabricated a poly(lactic-co-glycolic acid)(PLGA)/nano-hydroxyapatite (n-HA) composite scaffold grafted with the antibiotic vancomycin and loaded with the osteoinductive agent recombinant human bone morphogenic protein-2 (rhBMP-2) via polydopamine (DOPA) chemistry, whose therapeutic effects on IBD were determined. Methods: After examining the hydrophilicity, surface chemical composition, mechanical properties, and drug release of the PLGA/n-HA, PLGA/n-HA/VAN, and PLGA/n-HA/VAN+DOPA/rhBMP-2 composite scaffolds, pre-osteoblast MC3T3-E1 cells were seeded onto the scaffold surface to assess the biocompatibility and osteoconductive properties of the scaffolds in vitro. For in vivo experiments, the composite scaffolds contaminated with Results: The surface modification with DOPA/rhBMP-2 increased the hydrophilicity of PLGA/n-HA scaffolds. Vancomycin and BMP-2 were continuously and regularly eluted from the PLGA/n-HA/VAN+DOPA/rhBMP-2 scaffolds. The PLGA/n-HA/VAN+DOPA/rhBMP-2 scaffolds promoted MC3T3-E1 cell survival and proliferation and enhanced ALP activity and calcium deposition compared with the PLGA/n-HA and PLGA/n-HA/VAN scaffolds. Additionally, the PLGA/n-HA/VAN+DOPA/rhBMP-2 scaffolds significantly facilitated new bone formation and inhibited bone infection in IBD rabbit models. The rabbits implanted with the PLGA/n-HA/VAN+DOPA/rhBMP-2 scaffolds exhibited normal heart, lung, and kidney histologies and normal serum biochemical indices, suggesting the safety of the scaffolds. Conclusion: The 3D-printed PLGA/n-HA/VAN+DOPA/rhBMP-2 scaffolds exhibited both antibacterial and osteoinductive activities in IBD.

Indexed as

Bone Morphogenetic Protein 2OsteogenesisTissue ScaffoldsVancomycinAnimalsAnti-Bacterial AgentsBiocompatible MaterialsBone RegenerationCell LineDrug LiberationDurapatiteHumansIndolesMicePolylactic Acid-Polyglycolic Acid CopolymerPolymersAnti-Bacterial AgentsBiocompatible MaterialsBone Morphogenetic Protein 2DurapatiteIndolespolydopaminePolylactic Acid-Polyglycolic Acid CopolymerPolymersrecombinant human bone morphogenetic protein-2Recombinant ProteinsTransforming Growth Factor betaVancomycin3D printingbone regenerationinfected bone defectsPLGA/n-HApolydopaminerhBMP-2scaffoldsvancomycin

Identifiers

PMID40416730
PMCPMC12103859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.